Reducing Late Stage Drug Attrition through Predictive Toxicology 2011 Approaches in Drug Safety to Maximise Drug Candidate Success and Profitability
`The cost of developing an innovative drug ..... (is) now exceeding the widely quoted figure of US$802 million. Whatever the true cost, however, it is clear that late-stage clinical failures account for a large proportion of the expenses`
A. D. Schachter & M. F. Ramoni, 2007. Nature Reviews Drug Discovery 6, 107-108
As highlighted in the quote above late stage drug attrition accounts for a substantial amount of total development costs. Consequently, there is a strong impetus to improve predictive toxicology technology and assays to forecast toxicity and efficacy of compounds as early as possible in development without stifling the development of potentially safe, profitable drugs.
Past Events
Predictive Toxicology 2011 - 22-24 Feb 2011, America Square Conference Centre, London, United Kingdom (10511)
